FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3134770103> ?p ?o ?g. }

• W3134770103 endingPage "3414" @default.
• W3134770103 startingPage "3402" @default.
• W3134770103 abstract "TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa (ABBV-621) is a second generation TRAIL receptor agonist engineered as an IgG1-Fc mutant backbone linked to two sets of trimeric native single-chain TRAIL receptor binding domain monomers. This hexavalent agonistic fusion protein binds to the death-inducing DR4 and DR5 receptors with nanomolar affinity to drive on-target biological activity with enhanced caspase-8 aggregation and death-inducing signaling complex formation independent of FcγR-mediated cross-linking, and without clinical signs or pathologic evidence of toxicity in nonrodent species. ABBV-621 induced cell death in approximately 36% (45/126) of solid cancer cell lines in vitro at subnanomolar concentrations. An in vivo patient-derived xenograft (PDX) screen of ABBV-621 activity across 15 different tumor indications resulted in an overall response (OR) of 29% (47/162). Although DR4 (TNFSFR10A) and/or DR5 (TNFSFR10B) expression levels did not predict the level of response to ABBV-621 activity in vivo, KRAS mutations were associated with elevated TNFSFR10A and TNFSFR10B and were enriched in ABBV-621-responsive colorectal carcinoma PDX models. To build upon the OR of ABBV-621 monotherapy in colorectal cancer (45%; 10/22) and pancreatic cancer (35%; 7/20), we subsequently demonstrated that inherent resistance to ABBV-621 treatment could be overcome in combination with chemotherapeutics or with selective inhibitors of BCL-XL. In summary, these data provide a preclinical rationale for the ongoing phase 1 clinical trial (NCT03082209) evaluating the activity of ABBV-621 in patients with cancer. SIGNIFICANCE: This study describes the activity of a hexavalent TRAIL-receptor agonistic fusion protein in preclinical models of solid tumors that mechanistically distinguishes this molecular entity from other TRAIL-based therapeutics." @default.
• W3134770103 created "2021-03-15" @default.
• W3134770103 creator A5003574675 @default.
• W3134770103 creator A5007054845 @default.
• W3134770103 creator A5019593738 @default.
• W3134770103 creator A5022636146 @default.
• W3134770103 creator A5023133868 @default.
• W3134770103 creator A5030590415 @default.
• W3134770103 creator A5031829020 @default.
• W3134770103 creator A5033898620 @default.
• W3134770103 creator A5034078023 @default.
• W3134770103 creator A5036288399 @default.
• W3134770103 creator A5040158129 @default.
• W3134770103 creator A5040548612 @default.
• W3134770103 creator A5052624521 @default.
• W3134770103 creator A5060993657 @default.
• W3134770103 creator A5064784467 @default.
• W3134770103 creator A5064813104 @default.
• W3134770103 creator A5072190929 @default.
• W3134770103 creator A5073044716 @default.
• W3134770103 creator A5091743896 @default.
• W3134770103 date "2021-03-09" @default.
• W3134770103 modified "2023-10-18" @default.
• W3134770103 title "Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors" @default.
• W3134770103 cites W1964619821 @default.
• W3134770103 cites W1971563492 @default.
• W3134770103 cites W1974144614 @default.
• W3134770103 cites W1983863419 @default.
• W3134770103 cites W1991388076 @default.
• W3134770103 cites W2008465548 @default.
• W3134770103 cites W2019607817 @default.
• W3134770103 cites W2022265958 @default.
• W3134770103 cites W2044046394 @default.
• W3134770103 cites W2074106785 @default.
• W3134770103 cites W2084322562 @default.
• W3134770103 cites W2084376588 @default.
• W3134770103 cites W2106284224 @default.
• W3134770103 cites W2107610558 @default.
• W3134770103 cites W2110525250 @default.
• W3134770103 cites W2115147179 @default.
• W3134770103 cites W2154344002 @default.
• W3134770103 cites W2166215505 @default.
• W3134770103 cites W2166566481 @default.
• W3134770103 cites W2168632005 @default.
• W3134770103 cites W2169344120 @default.
• W3134770103 cites W2170364001 @default.
• W3134770103 cites W2172242534 @default.
• W3134770103 cites W2290145688 @default.
• W3134770103 cites W2319486658 @default.
• W3134770103 cites W2320870975 @default.
• W3134770103 cites W2414279676 @default.
• W3134770103 cites W2443320391 @default.
• W3134770103 cites W2515452313 @default.
• W3134770103 cites W2620490360 @default.
• W3134770103 cites W2754871120 @default.
• W3134770103 cites W2766023905 @default.
• W3134770103 cites W2769631482 @default.
• W3134770103 cites W2770858121 @default.
• W3134770103 cites W2799281825 @default.
• W3134770103 cites W2891164466 @default.
• W3134770103 cites W2904016068 @default.
• W3134770103 cites W2971799124 @default.
• W3134770103 cites W3093302259 @default.
• W3134770103 cites W4244578979 @default.
• W3134770103 doi "https://doi.org/10.1158/0008-5472.can-20-2178" @default.
• W3134770103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33687950" @default.
• W3134770103 hasPublicationYear "2021" @default.
• W3134770103 type Work @default.
• W3134770103 sameAs 3134770103 @default.
• W3134770103 citedByCount "18" @default.
• W3134770103 countsByYear W31347701032021 @default.
• W3134770103 countsByYear W31347701032022 @default.
• W3134770103 countsByYear W31347701032023 @default.
• W3134770103 crossrefType "journal-article" @default.
• W3134770103 hasAuthorship W3134770103A5003574675 @default.
• W3134770103 hasAuthorship W3134770103A5007054845 @default.
• W3134770103 hasAuthorship W3134770103A5019593738 @default.
• W3134770103 hasAuthorship W3134770103A5022636146 @default.
• W3134770103 hasAuthorship W3134770103A5023133868 @default.
• W3134770103 hasAuthorship W3134770103A5030590415 @default.
• W3134770103 hasAuthorship W3134770103A5031829020 @default.
• W3134770103 hasAuthorship W3134770103A5033898620 @default.
• W3134770103 hasAuthorship W3134770103A5034078023 @default.
• W3134770103 hasAuthorship W3134770103A5036288399 @default.
• W3134770103 hasAuthorship W3134770103A5040158129 @default.
• W3134770103 hasAuthorship W3134770103A5040548612 @default.
• W3134770103 hasAuthorship W3134770103A5052624521 @default.
• W3134770103 hasAuthorship W3134770103A5060993657 @default.
• W3134770103 hasAuthorship W3134770103A5064784467 @default.
• W3134770103 hasAuthorship W3134770103A5064813104 @default.
• W3134770103 hasAuthorship W3134770103A5072190929 @default.
• W3134770103 hasAuthorship W3134770103A5073044716 @default.
• W3134770103 hasAuthorship W3134770103A5091743896 @default.
• W3134770103 hasBestOaLocation W31347701031 @default.
• W3134770103 hasConcept C104317684 @default.
• W3134770103 hasConcept C121608353 @default.
• W3134770103 hasConcept C123894998 @default.
• W3134770103 hasConcept C126322002 @default.

• next